Breast Biopsies Market: Global Size, Share, Trends, Growth and Forecast, 2022-2032
Breast Biopsies Market: Overview and Definition
A breast biopsy is a diagnostic medical procedure in which a tissue sample is taken from the breast and examined under a microscope to check for the presence of cancer or other abnormal cells. Breast biopsies are typically performed when a lump or other abnormality is detected during a breast exam or imaging test, such as a mammogram or ultrasound.
The global breast biopsies market is expected to grow significantly in the coming years due to increasing incidence of breast cancer and a growing demand for minimally invasive diagnostic procedures. The market includes various types of breast biopsy procedures, such as core needle biopsy, fine needle aspiration biopsy, and surgical biopsy, and is segmented based on the mode of guidance used during the procedure, including ultrasound-guided, MRI-guided, and stereotactic-guided biopsies.
Breast cancer is one of the most significant health issues affecting women worldwide. Accordingly, it is the second-leading cause of cancer-related deaths in women globally.
As such, a biopsy, which is a confirmatory test that enables early diagnosis of a cancer/tumor or others in their early stages, resulting in speedy recovery, increased lifespan, reduced morbidity, and mortality is highly recommended by medical professionals for early detection. The procedure involves testing of small samples for detecting breast cancer by removing tissues or fluids from the suspicious areas of the patient’s body and testing them in the laboratory.
Breast biopsies are conducted using minimal invasive biopsy systems to cause minimal or no disfigurement and pain, depending on the result of these tests, the treatment plan is finalized and accordingly executed. There are different types of biopsy procedures available currently, which are recommended by the doctor based on the location, size, appearance, and other characteristics of the breast abnormality for appropriate choice making. The global breast biopsy market is expected to grow at a significant CAGR throughout the decade.
The growth of breast biopsy market is attributed towards major pertaining factors which includes the rising geriatric women’s population, the global increase in the prevalence of breast cancer, especially among women reaching a certain age group during and post menopause, growth in the awareness regarding breast cancer screening programs, emergence and growing inclination towards advanced technologies and minimally invasive and non-invasive breast-biopsy procedures, increasing number of breast cancer screening programs, increased awareness programs regarding importance of early detection of breast cancer, growing favorable government guidelines etc.
Additionally, the recommendation for breast biopsy especially the mammography guided stereotactic biopsy is rapidly grown in many developing countries. Also, the emergence of the 3D scanning technology has paved new ways for the market as 3D mammography has an additional advantage over 2D scans due to its comparatively lower usage of doses of x-rays at different angles for creating multiple sequential slides through the tissues, which in turn increases the level of demand and propels the growth of the market.
Moreover, majority of the total breast biopsies deploy surgical procedures, which create huge demand for surgical techniques compared to others. This is because surgical breast biopsies have much higher validity of confirming breast cancers. This creates a certain level of market demand among those undergoing these surgeries as a preventive measure for protection against any susceptible form of breast cancer, which thereby aids the growth of the market.
Furthermore, lack of physical exercise, improper diet and eating habits, increased alcohol consumption, high hormonal imbalance & exposure of skin to intense sunlight are factors which make women vulnerable to breast cancer. These lead to the increase in demand for breast biopsies and hence enhance the growth of the market.
However, factors such as substandard healthcare facilities, limited awareness among female population especially in the developing regions, high cost of procedure, uncertain and stringent regulatory approval procedures and product recalls, infection risks associated during breast biopsy procedures, requirement for technologically advanced machinery and highly qualified surgeons & doctors are expected to hinder the growth of the market.
BREAST BIOPSY MARKET SEGMENTATION:
- Needle Breast Biopsy
- Core Needle Biopsy (CNB)
- Fine Needle Aspiration Biopsy (FNAB)
- Vacuum-assisted Biopsy (VAB)
- Open Surgical Breast Biopsy
- Liquid Breast Biopsy
- Circulating Tumor Cells
- Circulating Tumor DNA (CtDNA)
- Biopsy Needles
- Guidance Systems
- Biopsy Tables
- Localization Wires
- Assay Kits
- Liquid Biopsy Instruments
By Guidance Technology:
- Image-Guided Biopsy
- Mammography-guided Stereotactic Biopsy
- Ultrasound-guided Biopsy
- MRI-guided Biopsy
- Other Guidance Techniques
- Liquid Biopsy
- NGS-based Biopsy
- PCR-based Biopsy
- Microarray-based Biopsy
- Early Cancer Screening
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring
- Ambulatory Surgical Centers
- Diagnostic Centers
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
The North American region has been dominating and is the largest regional market in the region for breast biopsies and is also projected to maintain its position. This is due to the rapidly increasing aging population in the region, the growing awareness for breast cancer, the early adoption of newer breast biopsy technologies, presence of highly advanced and equipped instruments, increasing supportive governmental initiatives and rising breast cancer cases. Major contributor in the region is the U.S.
The European region is the second largest regional market for breast biopsies owing to the presence of large female population and the highest prevalence of breast cancer occurring in the region. Major contributors in the region include the U.K, Belgium, Germany, Russia, Spain, France, and Poland etc.
The Asia-Pacific region is the fastest growing regional market for breast biopsies. This can be attributed to factors such as rising prevalence of breast cancer, the rising awareness about breast cancer among women and access to optimal treatment facilities in the region, rapid evolution of the healthcare infrastructure, growing investments and advancements by hospitals and breast care centers, growing number of awareness programs for the early detection of breast cancer, and the high government spending and initiatives on breast cancer research studies etc.
Lastly, though, the Latin American region is expected to witness steady amount of growth in the breast biopsy market, the Middle East and African region is anticipated to account for the lowest growth because of their underdeveloped healthcare system, lack of proper technical knowledge, and inadequate medical facilities in the region etc.
FEW KEY PLAYERS IN BREAST BIOPSY MARKET:
- Hologic Inc.
- Danaher Corporation
- Illumina Inc.
- Merit Medical Systems
- IZI Medical Products
- Scion Medical Technologies
- Biocept Inc.
- Bio-Rad Laboratories Inc.
- Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Leica Biosystems Nussloch
- R. Bard, Inc
- Becton and Dickinson Company
- Argon Medical Devices
- Cook Medical Incorporated
- Encapsule medical Devices
- Ethicon Endo Surgery
- Intact Medical Corporation
- Laboratory Corporation of America Holdings
- Other Players
In November 2020, 4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, announced that the U.S. Food & Drug Administration (FDA) granted the company ‘Breakthrough Device Designation’ for its first software-as-a-medical-device solution. The4D Q-plasia OncoReader Breast provides histopathologists with an adjunct technology to improve diagnostic accuracy of breast cancer features (g., its invasiveness, grades, etc.) solely from digitized histopathology images obtained via biopsies or resections.
In November 2020, NeoDynamics AB, a MedTech company dedicated to advancing diagnosis and care of breast cancer, announced that the Company received the first UK order from the Buckinghamshire Healthcare NHS Trust, London, of its pulse biopsy system, NeoNavia which is intended to be used under the ultrasound guidance.
Timeline Considered for Analysis:
- 2019: Base Year
- 2020 to 2025: Forecast Period
Research Scope and Deliverables
Overview & Executive Summary
Market Drivers, Trends, Challenges and Opportunities
Market Size and Forecast Projections
Macroeconomic Indicators of Various Countries Impacting the Growth of the Market
Extensive Coverage of Industry Players including Recent Product Launches and Market Activities
Porter’s Five Force Analysis
Market Segmentation Analysis:
Industry report analyzes the global Breast Biopsy market by the following segments:
- Guidance Technology
Customization: We also offers customization’s in the industry report as per the company’s specific needs.
Key Questions Answered in the Global Breast Biopsy Industry Report
- What is the overall market size in 2019? What will be the market growth during the forecast period i.e. 2020-2025?
- Which region would have high demand for product in the upcoming years?
- What are the factors driving the growth of the market?
- Which sub-market will make the most significant contribution to the market?
- What are the market opportunities for existing and entry-level players?
- What are various long-term and short-term strategies adopted by the market players?